Giridhar Prashanth, Mallick Supriya, Upadhyay Ashish Datt, Rath Goura K
Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Eur Arch Otorhinolaryngol. 2017 Oct;274(10):3803-3810. doi: 10.1007/s00405-017-4631-7. Epub 2017 Jun 9.
Ameloblastic carcinoma is a rare locally aggressive odontogenic neoplasm. These tumors are most commonly found to arise from mandible. Because of rarity, there is limited information about the clinical behaviour of such patients. We intended to perform this review of published literature to assess the demographic profile, pattern of care and assess survival outcomes. Two authors independently searched PubMed, Google search, and Cochrane library for eligible studies from 1950 until July 1 2016 published in English language. Data of 199 patients were retrieved from 94 publications for statistical analysis. Median age of the entire cohort was 49 years (range 7-91 years). The analysis revealed that a clear twofold higher incidence in male with male-to-female ratio was 2.4:1 (140:57). Mandible was found to be the commonest tumor location in 66.7% (n = 132) cases followed by maxilla (31.8%) (n = 64). The present analysis revealed that median PFS of 57 months (95% CI 39-120 months) with 5- and 10-year PFS was found to be 47.88 and 29.48%, respectively. Median OS for the entire cohort which was 122 months (95% CI 96-153 months) with 2- and 5-year OS for the entire cohort was 87.16 and 69.08%, respectively. In univariate analysis, patients with an R0 resection were found to have a favourable survival. In addition, patients with localized disease and younger age were found to have a better survival. Adjuvant radiation did not confer any survival advantage. The present analysis revealed excellent outcome for patients treated with an R0 resection. Older patients with high-risk factor may benefit from adjuvant radiation. Role of chemotherapy needs to be evaluated.
成釉细胞癌是一种罕见的具有局部侵袭性的牙源性肿瘤。这些肿瘤最常见于下颌骨。由于其罕见性,关于此类患者临床行为的信息有限。我们旨在对已发表的文献进行综述,以评估人口统计学特征、治疗模式并评估生存结果。两位作者独立检索了PubMed、谷歌搜索和Cochrane图书馆,以查找1950年至2016年7月1日期间以英文发表的符合条件的研究。从94篇出版物中检索到199例患者的数据进行统计分析。整个队列的中位年龄为49岁(范围7 - 91岁)。分析显示男性发病率明显高出两倍,男女比例为2.4:1(140:57)。下颌骨是最常见的肿瘤部位,占66.7%(n = 132),其次是上颌骨(31.8%)(n = 64)。目前的分析显示,中位无进展生存期为57个月(95%可信区间39 - 120个月),5年和10年无进展生存率分别为47.88%和29.48%。整个队列的中位总生存期为122个月(95%可信区间96 - 153个月),整个队列的2年和5年总生存率分别为87.16%和69.08%。在单因素分析中,R0切除的患者生存率良好。此外,局限性疾病患者和年轻患者生存率更好。辅助放疗未带来任何生存优势。目前的分析显示,接受R0切除治疗的患者预后良好。有高危因素的老年患者可能从辅助放疗中获益。化疗的作用需要评估。